CRY aims to pay weekly distributions based on the put option writing strategy. The ETF is actively managed, holding indirect exposure to CRCL-leveraged ETFs. Circle Internet Group, Inc. develops digital payment infrastructure and issues the USDC stablecoin, enabling blockchain-based payments and settlement services globally. The fund seeks 200% of the daily percentage change of the CRCL ETF, with capped gains. Regulatory constraints on risk might force strategy adjustments. The fund does not guarantee success and excludes direct investment in the CRCL ETF, leaving potential losses without premium offset. The underlying CRCL ETF targets 2x the daily stock performance, with long-term returns affected by daily rebalancing and compounding. The funds exposure ties closely to the interactive media and services industry due to the single underlying stock focus.

GraniteShares YieldBOOST CRCL ETF

Artivion Inc., established in 1984 and based in Kennesaw, Georgia, functions globally as a manufacturer, processor, and distributor of both medical devices and implantable human tissues. Previously known as CryoLife, Inc., the company underwent a rebranding to Artivion Inc. in January 2022. Artivion caters to a wide array of clients, including physicians, hospitals, various healthcare facilities, and specialized surgeons in cardiac, vascular, thoracic, and general fields. Their comprehensive product portfolio features BioGlue, a polymer formulated from bovine blood protein for use in cardiac, vascular, pulmonary, and general surgical procedures. They also provide the On-X line of prosthetic aortic and mitral heart valves, alongside the On-X ascending aortic prosthesis. Artivion extends its services to include cardiac preservation and offers PhotoFix, a bovine pericardial patch, as well as the E-vita OPEN PLUS and E-vita OPEN NEO hybrid stent graft systems. The company is a prominent supplier of specialized stent grafts designed for numerous aortic and arterial conditions. These include the E-xtra DESIGN ENGINEERING products for aortic vascular diseases, E-nside as an off-the-shelf option for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular treatment of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, E-ventus BX for renal and pelvic arteries, E-liac for aneurysmal iliac arteries and their side branches, and E-tegra for abdominal aortic aneurysms. Further offerings encompass synthetic vascular grafts for open aortic and peripheral surgeries, PerClot (an absorbable powdered hemostat), and cardiac laser therapy equipment such as the SolarGen 2100s Console. They also provide CryoVein and CryoArtery vascular preservation services, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures for mitral chordal replacement, and ascyrus medical dissection stents. Additionally, Artivion provides pyrolytic carbon coating services to other manufacturers in the medical device industry.

CRY Holdings & Sector Breakdown